A new period of consolidation for diagnostics
This article was originally published in Clinica
Executive Summary
Consolidation in the diagnostics sector is gathering pace. The number of deals has been steadily increasing over the last three years, from 31 in 2009 to 45 in 2011. In just the first four months of 2012, 15 deals were announced. Average deal value shot up from around $180m in 2009 to almost $700m so far in 2012, according to figures in a yet-to-be released study from the publishers of Clinica.
You may also be interested in...
Report Digest: Discussing What's Going On With Prostate Cancer Diagnosis And Treatment
In this edition of Report Digest, UK-based reporter Barnaby Pickering talks about the prostate cancer diagnostics and minimally invasive treatments markets with analyst Phil Greenfield. The two discuss ongoing developments in both treatment and diagnosis, while exploring driving and limiting factors for both.
Using Digital Tools To Unpick The Adherence Problem
An ambitious five-year public-private partnership plans to tackle non-adherence to medicines by giving patients EU-wide access to regulator-approved digital drug information. One year in, progress has been made in creating an app that could do just this.
In A First, FDA Approves Radioembolization Treatment For Liver Cancer In US
Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.